SCHEMBL308186

SCHEMBL308186

C1=CCc2cc3ccccc3cc2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP2A6 P11509 6/20 0.39
ALOX12 P18054 1/20 0.39
NQO2 P16083 1/20 0.38
HSD17B10 Q99714 4/20 0.36
CYP1A2 P05177 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP3A4 P08684 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CASP1 P29466 2/20 0.35
CASP7 P55210 2/20 0.35
HIF1A Q16665 2/20 0.35
TP53 P04637 2/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30003181 1.00 MEN1 (0.48) MEN1KMT2ACYP2A6ALOX12NQO2
SCHEMBL5968259 0.95 MEN1 (0.44) MEN1KMT2ACYP2A6ALOX12NQO2
SCHEMBL10521216 0.86 TSHR (0.44) MEN1KMT2AALDH1A1TDP1TSHR
SCHEMBL395756 0.78 MEN1 (0.40) MEN1KMT2ACYP2A6ALOX12NQO2
SCHEMBL7914941 0.75 MEN1 (0.52) MEN1KMT2ACYP2A6ALOX12NQO2
SCHEMBL14482014 0.75 MEN1 (0.52) MEN1KMT2ACYP2A6ALOX12NQO2
SCHEMBL29604701 0.75 MEN1 (0.52) MEN1KMT2ACYP2A6ALOX12NQO2
SCHEMBL1808685 0.75 MEN1 (0.52) MEN1KMT2ACYP2A6ALOX12NQO2
SCHEMBL31274423 0.75 MEN1 (0.52) MEN1KMT2ACYP2A6ALOX12NQO2
SCHEMBL29230355 0.75 MEN1 (0.52) MEN1KMT2ACYP2A6ALOX12NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118048167-A Preparation method of mesophase pitch, mesophase pitch and application 华东理工大学 2024-05-17 CN claimed
US-11358872-B2 Polymer for transferring graphene and transfer method of graphene using the same Research & Business Foundation Sungkyunkwan University (KR) 2022-06-14 US claimed
CN-108047243-B 2,3,6, 7-penta-pterene tetracarboxylic dianhydride compound and synthetic method thereof 华侨大学 2020-06-09 CN claimed
US-20190256357-A1 POLYMER FOR TRANSFERRING GRAPHENE AND TRANSFER METHOD OF GRAPHENE USING THE SAME Research & Business Foundation Sungkyunkwan University (KR) 2019-08-22 US claimed
US-20190071566-A1 NOVEL PHOSPHORUS COMPOUNDS, SYNTHESIS METHOD THEREOF, AND POLYCARBONATE RESIN COMPOSITION INCLUDING THEM Research & Business Foundation Sungkyunkwan University (KR) 2019-03-07 US claimed
EP-2643329-B1 IN-SITU ACTIVATION OF METAL COMPLEXES USED AS HYDROSILYLATION CATALYSTS MOMENTIVE PERFORMANCE MAT INC (US) 2016-07-27 EP claimed
WO-2014014274-A1 CARBON-SILICON COMPOSITE, METHOD FOR PREPARING SAME, AND CATHODE ACTIVE MATERIAL COMPRISING CARBON-SILICON COMPOSITE 주식회사 엘지화학 (KR) 2014-01-23 WO claimed
EP-2643329-A2 IN-SITU ACTIVATION OF METAL COMPLEXES USED AS HYDROSILYLATION CATALYSTS Momentive Performance Materials Inc. (US) 2013-10-02 EP claimed
WO-2012071358-A2 IN-SITU ACTIVATION OF METAL COMPLEXES CONTAINING TERDENTATE NITROGEN LIGANDS USED AS HYDROSILYLATION CATALYSTS MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2012-05-31 WO claimed
US-20120130106-A1 IN-SITU ACTIVATION OF METAL COMPLEXES CONTAINING TERDENTATE NITROGEN LIGANDS USED AS HYDROSILYLATION CATALYSTS CORNELL UNIVERSITY (US) 2012-05-24 US claimed
EP-1294732-B1 RUTHENIUM (II) COMPOUNDS FOR USE IN THE THERAPY OF CANCER UNIV EDINBURGH (GB) 2004-08-18 EP claimed
US-20040029852-A1 Ruthenium (ii) compounds for use in the therepy of cancer UNIVERSITY COURT, THE UNIVERSITY OF EDINBURGH, THE (GB) 2004-02-12 US claimed
US-6541597-B2 Resist resin having in its structure a bridged bond containing aliphatic ring; pattern excellent in transparency against short wavelength light and dry-etching resistance can be formed by alkali development with high resolution. KABUSHIKI KAISHA TOSHIBA (JP) 2003-04-01 US claimed
US-5490952-A REDUCING COMPLEX OF COPPER HALIDE OR CYANIDE AND ALKALI HALIDE WITH ALKALI SALT OF AROMATIC ANION; FOR SYNTHESIZING HIGHLY FUNCTIONAL ORGANIC COMPOUNDS UNIVERSITY OF NEBRASKA (US) 1996-02-13 US claimed
EP-0583429-A1 HIGHLY REACTIVE FORM OF COPPER AND REAGENTS THEREOF Board of Regents of the University of Nebraska (US) 1994-02-23 EP claimed
US-5231205-A Formation of silanes from magnesium salts and dienes BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1993-07-27 US claimed
WO-1992019623-A1 HIGHLY REACTIVE FORM OF COPPER AND REAGENTS THEREOF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1992-11-12 WO claimed
EP-0192492-B1 PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1992-01-02 EP claimed
US-4036681-A Delignification of lignocellulosic material with an alkaline pulping liquor containing a Diels Alder adduct of benzoquinone or naphthoquinone CANADIAN INDUSTRIES, LTD. (CA) 1977-07-19 US claimed
US-4036680-A Delignification of lignocellulosic material with a soda pulping liquor containing a Diels Alder adduct of benzoquinone or naphthoquinone in admixture with a nitro aromatic compound CANADIAN INDUSTRIES, LTD. (CA) 1977-07-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130106-A1 IN-SITU ACTIVATION OF METAL COMPLEXES CONTAINING TERDENTATE NITROGEN LIGANDS USED AS HYDROSILYLATION CATALYSTS TST, TPR, NBAS MEN1 2433/4885KMT2A 1662/4885CYP2A6 3790/4885
US-20040029852-A1 Ruthenium (ii) compounds for use in the therepy of cancer BRCA1, NFE2L2, RBBP7 MEN1 2690/4885KMT2A 1984/4885CYP2A6 535/4885
US-20190071566-A1 NOVEL PHOSPHORUS COMPOUNDS, SYNTHESIS METHOD THEREOF, AND POLYCARBONATE RESIN COMPOSITION INCLUDING THEM RPLP2, P2RY1, RB1 MEN1 1909/4885KMT2A 1926/4885CYP2A6 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.